Expert Tactics Over Etoposide Uncovered

Footnotes 1http://imagej.nih.gov/ij/ 2http://www.gelanalyzer.com Supplementary Material The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fnsyn.2016.00013/abstract Supplementary Figure 1 Characterization of a novel polyclonal anti-SPAR antibody. (A) Specificity testing of the anti-SPAR antibody. HEK293T cells were co-transfected with GFP-SPAR and either the control vector (Vector) or SPAR RNAi (for characterization of http://www.selleckchem.com/products/Temsirolimus.html these constructs see Richter et al., 2007). Western blotting of the corresponding cell lysates with anti-SPAR (left panel) and anti-GFP (right panel) showed reduction of GFP-SPAR in the presence of SPAR RNAi. (B) HEK293T cells were further transfected with GFP-SPAR, GFP-SPAR2 or GFP-SPAR3. Western blotting of the corresponding cell lysates with anti-SPAR or anti-GFP showed that this antibody is not cross-reactive to SPAR2 and SPAR3. Click here for additional data file.(158K, jpeg) Supplementary Figure 2 Analysis of PSD95 and LAPSER1 after ProSAPiP1 overexpression and knockdown in HSP90 mature primary hippocampal neurons. (A) Primary hippocampal cultures were infected with either FUGW empty vector (Vector) or GFP-ProSAPiP1 and stained for PSD95 (red) or LAPSER1 (red) on DIV28 as indicated. The intensity of LAPSER1-positive puncta was significantly increased. (B) Primary hippocampal cultures were infected with either Scr or RNAi and stained for PSD95 (red) or LAPSER1 (red) Etoposide price on DIV28 as indicated. No significant difference was observed. (A,B) Scale bar: 10 ��m. Statistical analysis was performed using unpaired two-sided t-test. *p